Defragmenting GRC: Confidence and Cost-Efficiency in a Time of Chaos - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Defragmenting GRC: Confidence and Cost-Efficiency in a Time of Chaos
The scope and complexity of GRC requirements are expanding so rapidly that businesses are struggling to fulfill them despite an increased willingness on industry's part to apply additional GRC resources.


Pharmaceutical Technology


Why unify now?

Most pharmaceutical companies have plenty of other technology on their shopping lists. They need good reasons to invest the time and resources required to create a foundation for enterprise-wide GRC. Here are just a few:

  • A firm may have an initiative on its plate that could provide the first step. Considering current issues is key—it may not be a corporate integrity agreement but it might be sales and marketing related to FCPA, or privacy, or IT governance.
  • It's better to prevent fragmentation than to fix it. Companies that don't establish a firm foundation for unified GRC now will wind up entrenched in fragmentation later.
  • The sooner a firm starts, the sooner it begins to regain control. By bringing coherence to GRC efforts now, companies can start to control costs and resources and lower risks.
  • Delays in implementation increase exposure to risk. When individual GRC teams must build their programs from scratch, it takes them time to create solutions. So companies that unify their GRC programs now will address their exposure more quickly and completely.
  • The need is urgent. C-level executives and board members should be willing to support initiatives that substantively reduce their personal exposure to risk while simultaneously protecting the interests of the business and its stakeholders.
  • It won't be that painful. With today's software-as-a-service solutions, enterprise GRC capabilities can be implemented without huge capital investments in IT. These investments can be leveraged as a firm works down its priority list of GRC initiatives.

Governance, risk, and compliance management pressures are escalating, but companies only have limited resources with which to respond. To properly allocate those limited resources, to maximize the results they achieve, and to achieve required results as quickly as possible, it is essential to bring some semblance of order to GRC efforts across the enterprise. Pharmaceutical companies that bring this kind of organization to GRC will reduce their risk with less effort and less cost than those that don't, allowing them to devote more of their resources to innovation, opportunity, and bottom-line growth.

Brett Curran is vice-president of GRC and privacy practices at Axentis, Inc., Skylight Office Tower, 1660 West Second Street, Suite 250, Cleveland, OH 44113,
. A former chief compliance officer and technology professional, Curran is a frequent speaker at GRC industry conferences, a contributor to the Open Compliance and Ethics Group as well as to IBM's Data Governance Council, and a blogger for "Compliance on Demand."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here